In this special episode of Eagle’s Eye View, Drs. Deepak Bhatt, Bina Ahmed and Roxana Mehran discuss highlights from Day 3 of the TCT 2022 late-breaking science, including PCSK9 Inhibition, FAVOR III China, and SCAAR. The ACC is providing coverage of the hottest TCT 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC’s Meeting Coverage page and follow the ACC on social media using the hashtag #TCT2022 to join the conversation.